| Summary: | Cancer patients experience more frequently patient harm than other patients, mostly from systemic anticancer treatment. To reduce avoidable patient harm from modern anticancer treatment such as immunotherapy and targeted therapies, precise and clinically relevant measurements are needed. The study aims through three different sub-studies to develop electronic methods for measuring automatically injuries in cancer patients, and investigate if electronic patient follow-up (ePRO) can prevent injuries, affect quality of life and survival in patients receiving immunotherapy cancer treatment. Research has shown that the recommended method for measuring patient harm is not specific or sensitive enough to detect cancer-related patient harm. In recent years, three damage measurement tools for cancer have been validated based on a manual retrospective review of the patient record. Based on existing technology and research, in sub-study 1 the aim is to develop and validate a fully automatic damage measurement tool for retrospective detection of damage in cancer patients receiving immunotherapy. The development of the technological solution is done by Datavarehuset Helse Nord and SAS Institute in an already existing solution (Nordic Clinical Analytics Framework - NCAF) which is used daily in all health trusts in Helse Nord, Northern Norway. In order to prevent avoidable patient harm, it is important to involve the patient in their own treatment. Research on follow-up with electronic patient reported outcome measures reveal more side effects, increased quality of life and survival in cancer patients. In sub-study 2, the technology developed in sub-study 1 is used to prospectively examine whether follow-up with ePRO compared to standard follow-up results in a decrease in adverse events. In part study 3, quality of life and survival are investigated with ePRO follow-up compared to standard follow-up. Sub study 1 is a retrospective diagnostic study. Sub-studies 2 and 3 are clinical cohort studies where a prospective ...
|
|---|